Idera Pharmaceuticals Inc. (IDRA)’s Financial Results Comparing With TCR2 Therapeutics Inc. (NASDAQ:TCRR)

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) and TCR2 Therapeutics Inc. (NASDAQ:TCRR) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Idera Pharmaceuticals Inc. N/A 113.48 59.88M -2.48 0.00
TCR2 Therapeutics Inc. N/A 0.00 54.66M -2.36 0.00

Table 1 highlights Idera Pharmaceuticals Inc. and TCR2 Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Idera Pharmaceuticals Inc. and TCR2 Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Idera Pharmaceuticals Inc. 0.00% -68.4% -60.4%
TCR2 Therapeutics Inc. 0.00% 0% 0%

Liquidity

The Current Ratio and Quick Ratio of Idera Pharmaceuticals Inc. are 8.2 and 8.2 respectively. Its competitor TCR2 Therapeutics Inc.?s Current Ratio is 34.6 and its Quick Ratio is 34.6. TCR2 Therapeutics Inc. can pay off short and long-term obligations better than Idera Pharmaceuticals Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Idera Pharmaceuticals Inc. and TCR2 Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Idera Pharmaceuticals Inc. 0 0 3 3.00
TCR2 Therapeutics Inc. 0 0 3 3.00

Idera Pharmaceuticals Inc. has a 329.04% upside potential and an average price target of $11.67. Competitively TCR2 Therapeutics Inc. has an average price target of $32, with potential upside of 82.75%. The results provided earlier shows that Idera Pharmaceuticals Inc. appears more favorable than TCR2 Therapeutics Inc., based on analyst view.

Institutional & Insider Ownership

Roughly 46.5% of Idera Pharmaceuticals Inc. shares are held by institutional investors while 0.8% of TCR2 Therapeutics Inc. are owned by institutional investors. Insiders held 0.7% of Idera Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 14.5% of TCR2 Therapeutics Inc.?s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Idera Pharmaceuticals Inc. -2.74% 12.25% -55.9% -71.46% -80.06% 2.53%
TCR2 Therapeutics Inc. 35.14% 0% 0% 0% 0% 46.98%

For the past year Idera Pharmaceuticals Inc. was less bullish than TCR2 Therapeutics Inc.

Summary

TCR2 Therapeutics Inc. beats Idera Pharmaceuticals Inc. on 6 of the 8 factors.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.